Linde (NYSE:LIN) and Polydex Pharmaceuticals (OTCMKTS:POLXF) are both oils/energy companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Linde and Polydex Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Linde 1 4 12 0 2.65
Polydex Pharmaceuticals 0 0 0 0 N/A

Linde currently has a consensus price target of $199.14, suggesting a potential downside of 1.76%. Given Linde’s higher probable upside, equities analysts clearly believe Linde is more favorable than Polydex Pharmaceuticals.

Volatility and Risk

Linde has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Polydex Pharmaceuticals has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500.

Valuation & Earnings

This table compares Linde and Polydex Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Linde $14.90 billion 7.41 $4.38 billion N/A N/A
Polydex Pharmaceuticals $4.94 million N/A $230,000.00 N/A N/A

Linde has higher revenue and earnings than Polydex Pharmaceuticals.

Insider and Institutional Ownership

72.9% of Linde shares are owned by institutional investors. 0.2% of Linde shares are owned by company insiders. Comparatively, 12.9% of Polydex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Dividends

Linde pays an annual dividend of $0.82 per share and has a dividend yield of 0.4%. Polydex Pharmaceuticals does not pay a dividend.

Profitability

This table compares Linde and Polydex Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Linde 23.52% 14.95% 8.44%
Polydex Pharmaceuticals 4.67% 4.10% 3.24%

Summary

Linde beats Polydex Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

Linde Company Profile

Linde plc operates as an industrial gas company in primarily North and South America, Europe, the Middle East, Africa, the Asia Pacific, and South Korea. The company offers oxygen, nitrogen, argon, rare gases, carbon monoxide, carbon dioxide, helium, hydrogen, electronic gases, specialty gases, and acetylene. It also designs and constructs turnkey process plants, such as olefin, natural gas, air separation, and hydrogen and synthesis gas plants. In addition, the company supplies wear-resistant and high-temperature corrosion-resistant metallic and ceramic coatings and powders for aircraft, energy, printing, primary metals, petrochemical, textile, and other industries; and manufactures a line of electric arc, plasma and wire spray, and high-velocity oxy-fuel equipment. It serves healthcare, petroleum refining, manufacturing, food, beverage carbonation, fiber-optics, steel making, aerospace, chemicals, and water treatment industries. Linde plc was founded in 1879 and is based in Guildford, the United Kingdom.

Polydex Pharmaceuticals Company Profile

Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

Receive News & Ratings for Linde Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Linde and related companies with MarketBeat.com's FREE daily email newsletter.